Combined effect of heptaplatin and ionizing radiation on human squamous carcinoma cell lines

Molecules and Cells

Volumn 19, Issue 1, 2005, Pages 143-148

  Ryu, Mi Ryeong ^a   Paik, Soon Young ^a   Chung, Su Mi ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Apoptosis; Cytotoxic Effect; Heptaplatin; Ionizing Radiation; Squamous Carcinoma Cell Line

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CISPLATIN; EPTAPLATIN; ANTINEOPLASTIC AGENT; MALONIC ACID DERIVATIVE; PLATINUM COMPLEX; RADIOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IONIZING RADIATION; SQUAMOUS CELL CARCINOMA; CELL SURVIVAL; DRUG SCREENING; EVALUATION; LARYNX TUMOR; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION EXPOSURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LARYNGEAL NEOPLASMS; LUNG NEOPLASMS; MALONATES; ORGANOPLATINUM COMPOUNDS; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS;

EID: 22844441864     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ahn, J. H., Kang, Y. K., Kim, T. W., Bahng, H., Chang, H. M., et al. (2002) Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemother. Pharmacol. 50, 104-110.
2. Berclaz, G., Gerber, E., Beer, K., Aebi, S., Greiner, R., et al. (2002) Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-year survival after radiochemotherapy. Int. J. Oncol. 20, 1313-1318.
3. Carter, S. K. (1984) Cisplatin-past, present and future; in Platinum Coordination Complexes in Cancer Chemotherapy, Hacker, M. P., Douple, E. B., and Krakoff, I. H. (eds.), pp. 359-376, Martinus Nijhoff Publishing, Boston.
4. Coughlin, C. T. and Richmond, R. C. (1989) Biological and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Sem. Oncol. 16, 31-43.
5. Dewit, L. (1987) Combined treatment of radiation and cis- diamminedichloro-platinum (II): a review of experimental and clinical data. Int. J. Radiat. Oncol. Biol. Phys. 13, 403-426.
6. Durant, J. R. (1980) Cisplatin: a clinical overview; in Cisplatin, Current Status and New Developments, Prestayko, A. W., Crooke, S. T., and Carter, S. K. (eds.), pp. 317-321, Academic Press, New York, NY.
7. Eastman, A. (1999) The mechanism of action of cisplatin: from adducts to apoptosis; in Chemistry and Biochemistry of a Leading Anticancer Drug, Bernhard, L. (ed.), pp. 111-134, Wiley-VCH, Basel.
8. Fram, R. J. (1992) Cisplatin and platinum analogues: recent advances. Curr. Opin. Oncol. 4, 1073.
9. Furuse, K., Kubota, K., Kawahara, M., Kodama, N., Ogawara, M., et al. (1995) Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 13, 869-875.
10. Gonzalez, V. M., Fuertes, M. A., Alonso, C., and Perez, J. M. (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol. Parmacol. 59, 657-663.
11. Hong, W. S., Kim, H. T., Kim, K. H., and Kim, D. K. (1995) In vitro antitumor activity of a new platinum complex, cis-malonato (4R, 5R)-4,5-bis(aminomethyl)-1,3-dioxolane-platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines. Anticancer Res. 15, 51-54.
12. Joiner, M. C., Lambin, P., and Marples, B. (1999) Adaptive response and induced resistance. C. R. Acad. Sci. III. 322, 167-175.
13. Joiner, M. C., Marples, B., Lambin, P., Short, S. C., and Turesson, I. (2001) Low-dose hypersensitivity: current status and possible mechanisms. Int. J. Rad. Oncol. Biol. Phys. 49, 379-389.
14. Kalendo, G. S. (2001) Different levels of radiation protection in tumor cell populations. Radiats. Biol. Radioecol. 41, 519-527.
15. Kelland, L. R. (1993) New platinum antitumor complexes. Crit. Rev. Oncol./Hematol. 15, 191-219.
16. Kim, D. K., Kim, G., Gam, J., Cho, Y. B., Kim, H. T., et al. (1994a) Synthesis and antitumor activity of a series of 2-substituted-4,5- bis(aminomethyl)-1,3-dioxolaneplatinum(II) complexes. J. Med. Chem. 37, 1471-1485.
17. Kim, D. K., Ahn, J. S., Ryu, G., Kim, K. H., Park, C. W., et al. (1994b) General pharmacology of cis-malonato(4R,5R)-4,5-bi(aminomet-hyl)-1,3-dioxolane- platinum(II) (SKI 2053R). Arzneim. Forsch. 44, 1080-1088.
18. Kim, D. K., Kim, H. T., Tai, J. H., Cho, Y. B., Kim, T. S., et al. (1995a) Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato-(4R,5R)-4,5-bis (aminomethyl)-1,3-dioxolane-platinum(II), as determined by ex vivo pharmacodynamics. Cancer Chemother. Pharmacol. 37, 1-6.
19. Kim, D. K., Kim, H. T., Cho, Y. B., Tai, J. H., Ahn, J. S., et al. (1995b) Antitumor activity of cis-malonato(4R,5R)-4,5-bis(aminomethyl)-1,3- dioxolane-platinum(II), a new platinum analogue, as an anticancer agent. Cancer Chemother. Pharmacol. 44, 441-445.
20. Kim, N. K., Im, S. A., Kim, D. W., Lee, M. H., Jung, C. W., et al. (1999) Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer 86, 1109-1115.
21. Kim, N. K., Kim, T. Y., Shin, S. G., Park, Y. L., Lee, J. A., et al. (2001) A phase I study of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-1,3- dioxolane]plaTINUM(II) in patients with advanced malignancies. Cancer 91, 1549-1556.
22. Kim, S. J., Kim, J. E., and Moon, I. S. (2004) Paraquat induces apoptosis of cultured rat cortical cells. Mol. Cells 17, 102-107.
23. Kohno, N., Kitahara, S., Tamura, E., and Tanabe, T. (2002) Concurrent chemoradio-therapy with low-dose cisplatin plus 5-Fluorouracil for the treatment of patients with unresectable head and neck cancer. Oncology 63, 226-231.
24. Kokubo, M., Nagata, Y., Nishimura, Y., Kimura, H., Shoji, K., et al. (2001) Concurrent chemoradiotherapy for oropharyngeal carcinoma. Am. J. Clin. Oncol. 24, 71-96.
25. Lee, Y. S., Kang, K. S., Shin, D. J., Cho, J. J., Kim, H. O., et al. (1992) Subacute toxicity of cis-malonato(4R,5R)-4,5-bis-(aminomethyl)-1,3- dioxolane-platinum(II) (SKI 2053R) in beagle dogs. Korean J. Toxicol. 8, 235-254.
26. Leichman, L., McDonald, B., Dindogru, F. A., Samson, M., and Vaitkevicius, V. K. (1984) An active drug in the treatment of disseminated gastric cancer. Cancer 53, 18-22.
27. Loeher, P. J. and Einhorn, L. H. (1984) Drugs five years later. Cisplatin. Ann. Intern. Med. 100, 704.
28. Merlano, M., Corvo, R., Margarino, G., Benasso, M., Rosso, R., et al. (1991) Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 67, 915-921.
29. Merlano, M., Vitale, V., Rosso, R., Benasso, M., Corvo, R., et al. (1992) Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N. Engl. J. Med. 327, 1115-1121.
30. Muggia, F. M. and Norris, K. J. (1989) Future of cancer chemotherapy with cisplatin. Semin. Oncol. 16, 123.
31. Non-small lung cancer collaborative group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J. 311, 889-890.
32. O'Dwyer, P. J., Johnson, S. W., and Hamilton, T. C. (1997) Pharmacology of cancer chemotherapy: cisplatin and its analogues; in Cancer: Principles and Practice of Oncology, De Vita, V. T., Hellman, S., and Rosenberg, S. A. (eds.), pp. 418-432, Lippincott-Raven, Philadelphia.
33. Potish, R. A., Twiggs, L. B., and Adcock, L. L. (1986) Effect of cisplatinum on tolerance to radiation therapy in advanced cervical cancer. Am. J. Clin. Oncol. 9, 387-391.
34. Reed, E., Dabholkar, M., and Chabner, B. A. (1996) Platinum analogues; in Cancer Chemotherapy and Biotherapy: Principles and Practice, Chabner, B. A. and Longo, D. I. (eds.), pp. 357, Lippincott-Raven, Philadelphia.
35. Rose, P. G. (2002) Chemoradiotherapy for cervical cancer. Eur. J. Cancer. 38, 270-278.
36. Rosenberg, B. (1999) Platinum complexes for the treatment of cancer: why the search goes on; in Cisplatin. In Chemistry and Biochemistry of a Leading Anticancer Drug, Bernhard, L. (ed.), pp. 3-27, Wiley-VCH, Basel.
37. Sause, W. T., Scott, C., and Taylor, S. (1995) Radiation Therapy Oncology Group (RTOG 88-08) Eastern Cooperative Oncology Group (ECOG 4588): preliminary results of a phase III trial in regionally advanced unresectable nonsmall cell lung cancer with minimum three year follow-up (Abstr). Int. J. Rad. Oncol. Biol. Phys. 32, 109.
38. Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., et al. (1994) Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 10, 263-270.
39. Soresi, E., Clerici, M., and Grilli, R. (1988) A randomized clinical trial comparing radiation therapy versus radiation therapy plus cis-dichlorodiamine (platinum III) in the treatment of locally advanced non-small cell lung cancer. Semin. Oncol. 15, 20-25.
40. Steel, G. G. and Peckham, M. J. (1979) Exploitable mechanism in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5, 85-91.
41. Tannock, I. F. (1989) Combined modality treatment with radiotherapy and chemotherapy. Radioth. Oncol. 16, 83-101.
42. Tannock, I. F. (1994) New perspectives in combined radiotherapy and chemotherapy treatment. Lung Cancer 10, 29-51.
43. Wong, L. C., Choo, Y. C., Choy, D., Sham, J. S., and Ma, H. K. (1989) Long-term follow-up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer. Gynecol. Oncol. 35, 159-163.